Do we really need five TNF antagonists? Or more insight into the use of existing options?

Eric M. Ruderman*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

1 Scopus citations
Original languageEnglish (US)
Article numberkeq016
Pages (from-to)1028-1029
Number of pages2
JournalRheumatology
Volume49
Issue number6
DOIs
StatePublished - Feb 19 2010

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this